NASDAQ:BEAM Beam Therapeutics (BEAM) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free BEAM Stock Alerts $23.03 -0.44 (-1.87%) (As of 02:04 PM ET) Add Compare Share Share Today's Range$22.81▼$23.8550-Day Range$23.47▼$45.0752-Week Range$16.95▼$49.50Volume422,943 shsAverage Volume1.44 million shsMarket Capitalization$1.90 billionP/E RatioN/ADividend YieldN/APrice Target$41.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Beam Therapeutics alerts: Email Address Beam Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside75.8% Upside$41.00 Price TargetShort InterestHealthy16.34% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 10 Articles This WeekInsider TradingSelling Shares$4.73 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.53) to ($5.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.11 out of 5 starsMedical Sector333rd out of 909 stocksBiological Products, Except Diagnostic Industry46th out of 156 stocks 4.2 Analyst's Opinion Consensus RatingBeam Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 5 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageBeam Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted16.34% of the outstanding shares of Beam Therapeutics have been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Beam Therapeutics has recently decreased by 6.08%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BEAM. Previous Next 1.9 News and Social Media Coverage News SentimentBeam Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Beam Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 14 people have searched for BEAM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,731,669.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Beam Therapeutics are expected to grow in the coming year, from ($5.53) to ($5.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -12.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -12.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Beam Therapeutics Stock (NASDAQ:BEAM)Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Read More BEAM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BEAM Stock News HeadlinesApril 5, 2024 | insidertrades.comGiuseppe Ciaramella Sells 4,534 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) StockApril 4, 2024 | insidertrades.comBeam Therapeutics Inc. (NASDAQ:BEAM) CFO Sells $174,925.52 in StockApril 24, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 2, 2024 | insidertrades.comBeam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $2,031,600.00 in StockApril 24, 2024 | americanbankingnews.comBeam Therapeutics (NASDAQ:BEAM) Receives Outperform Rating from WedbushApril 23, 2024 | seekingalpha.comBeam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue ProspectsApril 22, 2024 | msn.comBeam Therapeutics Stock (NASDAQ:BEAM): Investing in Cutting-Edge Gene EditingApril 19, 2024 | americanbankingnews.comBeam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Hold" from BrokeragesApril 24, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 18, 2024 | finance.yahoo.comBeam Therapeutics Inc. (BEAM)April 17, 2024 | americanbankingnews.comBeam Therapeutics Inc. (NASDAQ:BEAM) Short Interest Down 6.1% in MarchApril 14, 2024 | yahoo.comTV sex coach who uses ‘touch’ in therapy sued for rape by clientApril 13, 2024 | fool.caNASDAQ:BEAM (Beam Therapeutics)April 13, 2024 | msn.comNew Delhi: Radiation therapy facility started in Lady Hardinge HospitalApril 11, 2024 | finance.yahoo.comBeam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth PlansApril 9, 2024 | markets.businessinsider.comPoseida Therapeutics (PSTX) Gets a Buy from William BlairApril 5, 2024 | investing.comBeam Therapeutics president sells over $145k in company stockApril 3, 2024 | finance.yahoo.comTAE Life Sciences' Neutron Beam System Receives Acceptance, Allowing BNCT Clinical Trials to Begin in ChinaApril 3, 2024 | bizjournals.comBeam Dynamics, Three Strands Recovery Wear take home top prizes at Winston Starts’ pitch competitionApril 2, 2024 | markets.businessinsider.comBeam Therapeutics: A Buy Rating Amidst Gene Editing Industry DevelopmentsApril 2, 2024 | msn.comGene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad CholesterolApril 2, 2024 | msn.comHelen Flanagan beams as she poses with her young son following psychosis diagnosisMarch 30, 2024 | msn.comIs Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game?March 30, 2024 | yahoo.comLaw enforcement break windows, kick down doors as they search Beam Hall and the Student UnionMarch 29, 2024 | msn.comThe 6 Best Cold Laser Therapy Devices for At-Home HealingMarch 29, 2024 | yahoo.comThese Cold Laser Therapy Devices Will Help Transform Your SkinMarch 29, 2024 | msn.comBlind Dog Recovers from Losing Eyes & Ear to Become Therapy DogSee More Headlines Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/24/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BEAM CUSIPN/A CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees436Year Founded2017Price Target and Rating Average Stock Price Target$41.00 High Stock Price Target$57.00 Low Stock Price Target$20.00 Potential Upside/Downside+74.7%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-132,530,000.00 Net Margins-35.09% Pretax Margin-34.72% Return on Equity-15.90% Return on Assets-9.75% Debt Debt-to-Equity RatioN/A Current Ratio5.89 Quick Ratio5.89 Sales & Book Value Annual Sales$377.71 million Price / Sales5.07 Cash FlowN/A Price / Cash FlowN/A Book Value$12.04 per share Price / Book1.95Miscellaneous Outstanding Shares81,660,000Free Float78,065,000Market Cap$1.92 billion OptionableOptionable Beta1.77 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. John M. Evans M.B.A. (Age 46)CEO & Director Comp: $1.11MDr. Giuseppe Ciaramella Ph.D. (Age 55)President Comp: $933.2kMs. Terry-Ann Burrell M.B.A. (Age 47)CFO & Treasurer Comp: $711.15kDr. Feng Zhang Ph.D.Co-FounderDr. David R. Liu Ph.D.Co-FounderDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Nicole Gaudelli Ph.D.Co-FounderDr. Alexis Komor Ph.D.Co-FounderDr. Manmohan Singh Ph.D.Chief Technology OfficerDr. Gopi Shanker Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsGinkgo BioworksNYSE:DNATwist BioscienceNASDAQ:TWSTFusion PharmaceuticalsNASDAQ:FUSNRecursion PharmaceuticalsNASDAQ:RXRXSana BiotechnologyNASDAQ:SANAView All CompetitorsInsiders & InstitutionsFishman Jay A Ltd. MIBought 10,000 shares on 4/23/2024Ownership: 0.012%Sumitomo Mitsui Trust Holdings Inc.Bought 3,726 shares on 4/19/2024Ownership: 2.892%SteelPeak Wealth LLCBought 7,505 shares on 4/18/2024Ownership: 0.009%Thrive Wealth Management LLCBought 6,925 shares on 4/16/2024Ownership: 0.008%DLK Investment Management LLCBought 7,225 shares on 4/13/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions BEAM Stock Analysis - Frequently Asked Questions Should I buy or sell Beam Therapeutics stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last twelve months. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares. View BEAM analyst ratings or view top-rated stocks. What is Beam Therapeutics' stock price target for 2024? 13 Wall Street research analysts have issued 12-month price targets for Beam Therapeutics' stock. Their BEAM share price targets range from $20.00 to $57.00. On average, they expect the company's stock price to reach $41.00 in the next year. This suggests a possible upside of 75.8% from the stock's current price. View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts. How have BEAM shares performed in 2024? Beam Therapeutics' stock was trading at $27.22 at the start of the year. Since then, BEAM shares have decreased by 14.3% and is now trading at $23.32. View the best growth stocks for 2024 here. Are investors shorting Beam Therapeutics? Beam Therapeutics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 13,450,000 shares, a drop of 6.1% from the March 15th total of 14,320,000 shares. Based on an average daily trading volume, of 1,390,000 shares, the short-interest ratio is currently 9.7 days. View Beam Therapeutics' Short Interest. When is Beam Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our BEAM earnings forecast. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) announced its quarterly earnings data on Tuesday, February, 27th. The company reported $1.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $2.42. The company earned $316.20 million during the quarter, compared to the consensus estimate of $34.16 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 15.90% and a negative net margin of 35.09%. The company's revenue for the quarter was up 1481.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.54) earnings per share. What ETFs hold Beam Therapeutics' stock? ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Innovation ETF (ARKK), Horizon Kinetics Medical ETF (MEDX), WisdomTree BioRevolution Fund (WDNA) and Franklin Genomic Advancements ETF (HELX). What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC). When did Beam Therapeutics IPO? Beam Therapeutics (BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Beam Therapeutics' major shareholders? Beam Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (2.89%), Fishman Jay A Ltd. MI (0.01%), SteelPeak Wealth LLC (0.01%), DLK Investment Management LLC (0.01%), Thrive Wealth Management LLC (0.01%) and Riverview Trust Co (0.00%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Beam Therapeutics have any subsidiaries? The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..Read More This page (NASDAQ:BEAM) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Goldtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
